All In Biotech

NDA 218980 · Eton

Khindivi

Hydrocortisone · Oral · Corticosteroid

Last checked: Nov 19, 2026Latest source record: May 28, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

May 28, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

753

149 Phase 3, 82 recruiting

FAERS reports

68,202

56,400 serious, 10,069 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 1, 2026.

KHINDIVI is indicated as replacement therapy in pediatric patients 5 years of age and older with adrenocortical insufficiency. KHINDIVI is a corticosteroid indicated as replacement therapy in pediatric patients 5 years of age and older with adrenocortical insufficiency. ( 1 ) Limitations of Use KHINDIVI is not approved for increased dosing during periods of stress or acute events. Use a different hydrocortisone-containing drug product for stress dosing [see Warnings and Precautions (5.1) ] . Limitations of Use KHINDIVI is not approved for increased dosing during periods of stress or acute events. Use a different hydrocortisone-containing drug product for stress dosing [(see Warnings and Precautions (5.1) ] .

Mechanism: Hydrocortisone is a glucocorticoid. Glucocorticoids, adrenocortical steroids, cause varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • KHINDIVI · HYDROCORTISONE 1MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Hydrocortisone" as an intervention, any sponsor and status, largest first.

All 753 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use9,685
  • drug ineffective7,637
  • fatigue6,088
  • condition aggravated5,564
  • nausea5,128
  • rash5,024
  • diarrhoea4,563
  • headache4,524
  • pain4,511
  • dyspnoea4,399
  • arthralgia4,389
  • pyrexia4,050

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004437
2005555
2006511
2007547
2008613
2009735
2010847
20111,083
20121,768
20131,542
20141,779
20152,440
20162,886
20173,318
20184,828
20194,318
20205,259
20215,485
20226,149
20236,108
20246,436
20256,229
20264,325

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,629 on PubMed

Sponsor: Eton

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.